Trump announces phased 100-200% tariffs on imported generic drugs
On July 21-22, 2026, U.S. President Donald Trump announced a phased tariff regime on imported generic drugs, with zero tariffs until August 2028, then 100% for one year, escalating to 200% thereafter. The policy aims to reshore pharmaceutical manufacturing to the U.S., citing national security. India, which supplies nearly 50% of U.S. generic prescriptions and exported $9.7 billion in drugs in 2025, faces major exposure. Indian firms warned costs would be passed to American consumers, while the Nifty Pharma index fell 1.31%.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Source updates available; summary pending
Summary pending
Cross-source coverage
Reporting timeline
Trump's 100% Tariffs on Generic Meds Threaten Headaches at Drugstore Checkouts
President Trump threatened 100% tariffs on imported generic drugs starting August 2028, doubling to 200% a year later, unless manufacturers reshore production to the US. Unlike patented drugmakers, which have pledged over $500 billion in US investment to avoid tariffs, generic drugmakers operate on thin margins and are based mainly in Asia and Europe. Industry leaders, including Dr. Reddy's CEO, stated that the costs will be passed on to US consumers, insurers, and healthcare providers. The announcement caused stock declines for major generic drugmakers: Sandoz fell 4%, Lupin closed down 4.3%, and Dr. Reddy's tumbled 9%. The policy aims to reduce US reliance on foreign generic drug manufacturing but risks raising prices for the 90% of US prescriptions that are generic.
Read sourceTrump's 200% generic drug tariff threat would harm Americans, Indian pharma warns
US President Donald Trump announced on July 22, 2026, via social media that generic drug imports will face zero tariffs until August 1, 2028, then 100% for one year, and 200% thereafter. The policy aims to reshore pharmaceutical manufacturing. Indian pharmaceutical companies, which supply nearly half of US generic prescriptions and exported $9.7 billion worth of drugs to the US in 2025, warned that higher tariffs would increase medicine costs for American consumers. Industry executives like Dr. Reddy's CEO Erez Israeli said moving operations to the US overnight is impractical and costs would be passed on. The Nifty Pharma index fell 1.31% on the announcement. The Global Trade Research Initiative noted India is highly exposed, but many generics may remain competitive due to low pricing. Indian firms already operate over 40 US facilities.
Read sourceTrump gives generic drugmakers ultimatum: manufacture in US by August 2028 or face up to 200% tariff
US President Donald Trump announced on July 22, 2026, that generic drugs imported into the United States will face escalating tariffs starting August 2028. Under the plan, imports will remain duty-free until August 1, 2028, then face a 100% tariff for one year, followed by a permanent 200% tariff. The policy aims to reshore pharmaceutical manufacturing and reduce reliance on foreign supply chains. The announcement has major implications for India, which supplies nearly half of US generic prescriptions and exported $9.7 billion in pharmaceuticals to the US in 2025. Indian drugmakers warned that higher tariffs would increase medicine costs for American consumers. The Nifty Pharma index fell 1.31% on the news. Industry executives adopted a cautious stance, noting that relocating manufacturing is not feasible overnight and that costs would likely be passed on to patients. Indian companies already operate over 40 facilities in the US.
Read sourceShow 5 older updatesHide older updates
EU Dismisses Trump's Threat of 100% Tariffs on Generic Drug Imports
US President Donald Trump announced on Truth Social that generic medicines imported into the US could face 100% tariffs starting August 1, 2028, escalating to 200% a year later, aiming to reshore pharmaceutical production. The move contradicts the EU-US trade deal signed in April, which explicitly exempts off-patent generics from tariffs (currently at 0%). The European Commission expects the US to uphold the commitment, while the European Parliament's lead negotiator Bernd Lange called the announcement a threat that would violate the joint statement if enacted. Trade group Medicines for Europe warned that Europe is the sole supplier for nearly 700 active pharmaceutical ingredients approved in the US, stressing the need to maintain open trade. Sandoz, a major Swiss generics manufacturer, said it is too early to assess implications. The US Trade Representative has not yet issued an official statement.
Read sourceTrump Unveils Phased Generic Drug Tariffs to Reshore Pharmaceutical Manufacturing
President Donald Trump announced a phased tariff regime on imported generic drugs, announced via Truth Social on July 21, 2026. The policy grants a two-year tariff-free window starting August 1, 2026, followed by a 100% tariff in August 2028, escalating to 200% thereafter for non-compliant importers. Trump framed the escalation as a penalty for companies failing to invest in U.S. plants, aiming to reshore generic pharmaceutical production. This extends earlier April 2026 actions under Section 232 that imposed 100% tariffs on patented drugs and APIs unless manufacturers agreed to domestic production or Most Favored Nation pricing. The policy has major implications for India, which supplies nearly 50% of U.S. generic medicines by volume, with firms like Sun Pharma, Dr. Reddy's, Cipla, Lupin, and Aurobindo Pharma exposed. Analysts warn of long-term pressure, especially given upstream reliance on Chinese APIs.
Trump Unveils Phased Generic Drug Tariffs to Reshore Pharmaceutical Manufacturing
President Donald Trump announced a phased tariff regime on imported generic drugs, granting a two-year tariff-free window starting August 1, 2026, followed by a 100% tariff in August 2028 and 200% thereafter. The policy, announced via Truth Social on July 21, aims to pressure pharmaceutical companies to shift production to the United States, citing national security and economic independence. This builds on earlier April 2026 tariffs on patented drugs and APIs under Section 232. The move has significant implications for India, which supplies nearly 50% of US generic medicines by volume, with major firms like Sun Pharma, Dr. Reddy's, Cipla, Lupin, and Aurobindo Pharma exposed. Analysts warn of long-term pressure on Indian exporters, compounded by upstream reliance on Chinese APIs, though some Indian companies have already expanded US manufacturing footprints.
Read sourceTrump Unveils Phased Generic Drug Tariffs to Reshore Pharmaceutical Manufacturing
President Donald Trump announced a phased tariff regime on imported generic drugs, aiming to incentivize pharmaceutical companies to shift production to the United States. Announced via Truth Social on July 21, the policy grants a two-year tariff-free window starting August 1, 2026, followed by a 100% tariff in August 2028 and a 200% tariff thereafter for non-compliant importers. This extends earlier April 2026 actions under Section 232 that imposed tariffs on patented drugs and APIs, with generics initially exempted. The policy has significant implications for India, which supplies nearly 50% of US generic medicines by volume. Major Indian firms such as Sun Pharmaceutical, Dr. Reddy's, Cipla, Lupin, and Aurobindo Pharma face long-term pressure, though some have already expanded US manufacturing. Upstream reliance on Chinese APIs adds further vulnerability.
Trump sets 100% tariff on generic drugs with two-year delay
US President Donald Trump has announced a 100% tariff on imported generic drugs, with a two-year delay before implementation. The policy targets rising drug costs as a key voter concern ahead of the 2026 midterm elections. The tariff will take effect in August 2028, then double to 200% a year later in August 2029. The move gives generic drug manufacturers two years to adjust supply chains or shift production. The announcement was reported by The Business Times Singapore on July 22, 2026, and highlights the administration's focus on pharmaceutical pricing as a political issue.
Read source